MarineMax Inc

Several stocks made significant midday moves on Monday. MarineMax soared 46% after agreeing to be sold to Blackstone Infrastructure's Safe Harbor Marinas for $53 a share in cash, or $1.5 billion, with the deal expected to close by the end of 2026. Varex Imaging climbed 48% after Teledyne Technologies agreed to buy the imaging component maker for $18.90 a share in cash, a deal expected to close in early 2027. Sionna Therapeutics collapsed 92% after its cystic fibrosis drug failed to meet key endpoints in a proof-of-concept trial, and the company said it would not advance the drug. Other notable movers included NetApp, which gained 6% after Morgan Stanley upgraded it to equal weight from underweight, and Verisk Analytics, which tumbled more than 5% after a Delaware judge ruled it must proceed with a $2.35 billion acquisition of AccuLynx. Apple dipped 2% after Jefferies downgraded the stock to underperform from hold, citing canceled plans for an all-glass iPhone. Intel fell nearly 3% after announcing a $15 billion common stock offering for general corporate purposes.

Tenax Therapeutics and Sionna Therapeutics shares plunged in premarket trading after their respective clinical trials failed, while MarineMax jumped on a reported buyout by Blackstone-owned Safe Harbor Marinas. Tenax stock fell 84.2% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, showing no statistically significant improvement in six-minute walk distance versus placebo with a p-value of 0.63. Sionna shares dropped 92.1% after its Phase 2a trial of SION-719 failed to demonstrate meaningful CFTR function improvement, with a placebo-adjusted sweat chloride change of just -1.0 mmol/L and a p-value of 0.7. MarineMax surged more than 34% after Reuters reported Safe Harbor is close to acquiring the boat retailer for $1.5 billion including debt, or about $53 per share in cash, a substantial premium to Friday's close of $35.68. AAON gained over 10.6% after its second-quarter results apparently beat expectations, while Silence Therapeutics rose 16.2% ahead of a conference call on its Phase 2 SANRECO trial. Dole fell 4.2% after missing second-quarter earnings and revenue estimates, and AirSculpt Technologies dropped 18.4% on weaker quarterly results with revenue down 3% year-over-year.

MarineMax announced it accepted a buyout offer from Safe Harbor at $53.00 per share in an all-cash transaction valued at approximately $1.5 billion. The deal followed a competitive strategic review process led by the board and management with independent advisors. The transaction is expected to close by the end of 2026, subject to regulatory and shareholder approvals, and the board recommends shareholders vote in favor. MarineMax shares surged 33.8% to $47.75 in premarket trading.